Stocks · News reference
BioVie Says Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID Did Not Achieve Statistical Significance On Any Endpoint In Overall Population, With Significant Results Only In Pre-Specified Subgroups; To Discuss Topline Results On September 15 Call
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
What's Going On With BioVie Stock on Tuesday?
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
BioVie shares are trading lower. The company announced topline results from Phase 2 ADDRESS‑LC trial evaluating Bezisterim for the treatment of neurological symptoms associated with long COVID.
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times